Archives

Choose a date range

From To

Choose one or more categories

Categories:



 


FDA approves Afrezza to treat diabetes

Monday, June 30, 2014 02:29 PM

The FDA has approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal.

More... »

WIRB Copernicus Group

U.S. Oncology Research launches trial for preventing chemotherapy-induced hair loss

Monday, June 30, 2014 01:01 PM

U.S. Oncology Research—one of the largest community-based cancer research programs in the nation—and Baylor College of Medicine recently have launched a clinical trial to study a scalp cooling system designed to prevent chemotherapy-induced hair loss (alopecia). To date, 15 patients have been enrolled, and the study now is available at three U.S. Oncology Research sites.

More... »

CRF Health eCOA webinar series

The Pulse on Global Trials

Monday, June 30, 2014 07:00 AM

At this month’s DIA annual meeting in San Diego, I gave a talk on leveraging the digital ecosystem for patient recruitment.

More... »

Ampio Pharmaceuticals closes enrollment in the OptimEyes study

Friday, June 27, 2014 01:54 PM

Ampio Pharmaceuticals has informed the Transplant and Ophthalmology Division of the FDA of its intent to reduce the patient sample size in the OptimEyes study for the treatment of diabetic macular edema (oral treatment with Optina). This trial was intended to enroll 450 patients and was powered at 95%. The present enrollment of over 355 patients provides an adequate power of 88%, which the company believes is more than sufficient for statistical evaluation.

More... »

Aurinia Pharmaceuticals initiates phase IIb trial of Voclosporin for lupus nephritis

Friday, June 27, 2014 01:19 PM

Aurinia Pharmaceuticals has enrolled the first patient in its planned phase IIb clinical trial to evaluate the efficacy of voclosporin as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition. The Lupus Foundation of America believes there are as many as 1.5 million people in the U.S. with systemic lupus erythematosus (SLE), approximately 40% to 70% of whom will develop LN.

More... »

Jennifer Doudna, Emmanuelle Charpentier win award for biomedical research

Friday, June 27, 2014 12:53 PM

Johnson & Johnson has named Dr. Jennifer Doudna of the University of California at Berkeley and the Howard Hughes Medical Institute, and Dr. Emmanuelle Charpentier, of the Hannover Medical School and Helmholtz Center for Infection Research (HZI), Germany and the Laboratory for Molecular Infection Medicine Sweden (MIMS), Umea University, Sweden, the winners of the 2014 Dr. Paul Janssen Award for Biomedical Research. Their collaboration led to the discovery of a new method for precisely manipulating genetic information in ways that should produce new insights in health and disease, and may lead to the discovery of new targets for drug development.

More... »

Massachusetts becomes 7th state to pass law allowing pharmacy substitution of interchangeable biosimilars

Friday, June 27, 2014 12:08 PM

Massachusetts this week became the seventh state to allow for the substitution at the pharmacy of biosimilars deemed “interchangeable” with branded original drugs—legislation being enacted on a state-by-state basis.

More... »

St. Jude Children's Research Hospital names James R. Downing CEO

Friday, June 27, 2014 11:58 AM

St. Jude Children's Research Hospital has appointed James R. Downing, M.D., as its new CEO, effective July 15. Downing most recently was the deputy director, executive vice president and scientific director of the hospital. Downing's primary focus immediately upon assuming the CEO office will be to oversee a new era of clinical, research and infrastructure expansion throughout the St. Jude global network. He succeeds Dr. William E. Evans, who is retiring from the position after 10 years and returning full time to his long-standing pharmacogenomics research program at St. Jude.

More... »

Liomont, Oncobiologics partner to launch biosimilars in Mexico

Friday, June 27, 2014 11:13 AM

Oncobiologics, a privately held biopharmaceutical company, and Laboratorios Liomont, a Mexico City-based pharmaceutical company, have partnered for the development, manufacture and commercialization of biosimilar monoclonal antibody products for the Mexican market. The agreement includes exclusive commercialization in Mexico by Liomont of two biosimilars developed by Oncobiologics.

More... »

Alzheimer's Drug Discovery Foundation, OnDeckBiotech partner

Friday, June 27, 2014 11:12 AM

The Alzheimer's Drug Discovery Foundation (ADDF) and OnDeckBiotech, a Boston-based software company providing software tools for biotech, pharma and R&D service vendors, are partnering to provide a new platform technology for ADDF ACCESS, an open-access database that provides a network of CROs, drug development consultants and educational resources focused for diseases of the central nervous system (CNS).

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs